Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on June 18, 2018, 10:27:30 am

Title: Experimental Hepatitis B Drug, JNJ-6369, Shows Promise in Early Trial
Post by: Hep Editors on June 18, 2018, 10:27:30 am
An early ongoing study of an experimental treatment for hepatitis B virus (HBV), JNJ-6379, has highlighted the promise of the agent, MedPage Today reports. Researchers have already begun studying it in a more advanced trial.

Presenting their findings at the 52nd International Liver Congress in Paris, researchers conducted a Phase Ib study of the effects of JNJ-6379 on HBeAg-positive or HBeAG-negative people with chronic HBV who had a viral load greater than 2,000 and an ALT liver enzyme level no greater than 2.5 times that of their AST liver enzyme level.

Read more...
https://www.hepmag.com/article/experimental-hepatitis-b-drug-jnj6369-shows-promise-early-trial